TIDMHIK

RNS Number : 4598S

Hikma Pharmaceuticals Plc

02 October 2017

Hikma Pharmaceuticals PLC

Total Voting Rights and Capital

LONDON, 2 October 2017 - In accordance with the UK Financial Conduct Authority's (the "FCA") DTR 5.6.1, Hikma Pharmaceuticals PLC (LEI: 549300BNS685UXH4JI75) (LSE: HIK) (NasdaqDubai: HIK) notifies the market that as at 30 September 2017, its share capital consists of 240,651,333 ordinary shares with voting rights. There are nil shares held in treasury.

The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, Hikma Pharmaceuticals PLC under the FCA's DTR's.

- ENDS -

Enquiries

 
 Hikma Pharmaceuticals PLC 
 Peter Speirs 
  Company Secretary           +44 20 7399 2760

About Hikma

Hikma Pharmaceuticals PLC is a fast growing pharmaceutical group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products. Hikma's operations are conducted through three businesses: "Branded", "Injectables" and "Generics" based primarily in the Middle East and North Africa ("MENA") region, where it is a market leader, the United States and Europe. In 2016, Hikma achieved revenues of $1,950 million and profit attributable to shareholders of $155 million.

This information is provided by RNS

The company news service from the London Stock Exchange

END

TVREALEAEDKXFFF

(END) Dow Jones Newswires

October 02, 2017 10:36 ET (14:36 GMT)

Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From May 2024 to Jun 2024 Click Here for more Hikma Pharmaceuticals Charts.
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jun 2023 to Jun 2024 Click Here for more Hikma Pharmaceuticals Charts.